Table 1.

Characteristics of the studies included

Authors	Cooperative group	Population	Age criteria	Follow-up (months)	N		Median age		Conditioning		GVHD prophylaxis
					TA	AR	TA	AR	Auto	RIC
Bjorkstrand	EBMT	Newly diagnosed MM patients	<70	61	249	108	57	54	Mel200	Flu + TBI 200 cGy	CSA + MMF
Garban, Moreau	IFM	Chr 13 del + β2 microglobulin >3 mg/L	<65	56	219	65	58	54	Mel200, Mel220	Bu + Flu + ATG	CSA + MTX
Giaccone, Bruno	NA	Newly diagnosed MM patients	≤65	86	82	80	54 (mean)	54 (mean)	Mel200, Mel100–200	TBI 200 cGy	CSA + MMF
Knop	DSMM	Chr 13 del by FISH	≤60	41	73	126	56	52	Mel200	Flu + Mel + /− ATG	NA
Krishnan (SR)	BMT-CTN	Not meeting criteria for high risk	≤70	40	436	189	55	53	Mel200	TBI 200 cGy	CSA + MMF
Krishnan (HR)	BMT-CTN	Chr13 del by metaphase cytogenetics or β2 microglobulin >4 mg/L	≤70	40	48	37	57	51	Mel200	TBI 200 cGy	CSA + MMF
Rosinol	PETHEMA	Not achieving CR/nCR after first autologous	<65	62	85	25	55	52	Mel200 or CVB	Flu + Mel	CSA + MTX

Abbreviations: AR = autologous + reduced intensity allogeneic transplantation; ATG = antithymocyte globulin; BMT-CTN = Blood and Marrow Transplant Clinical Trials Network; Bu = busulfan; CVB = cyclophosphamide, etoposide, BCNU; DSMM = Deutsche Studiengruppe Multiples Myelom; EBMT = European BMT; Flu = fludarabine; HR = high risk; IFM = Intergroupe Francophone du Myelome; Mel200 = Melphalan 200 mg/m²; MM = multiple myeloma; MMF = mycophenolate mofetil; NA, not applicable; PETHEMA = Programa para el Estudio de la Terapéutica en Hemopatía Maligna; SR = standard risk; TA = tandem autologous transplantation; TBI = total body irradiation.